HemaSure
This article was originally published in The Gray Sheet
Executive Summary
Private placement of 3.7 mil. shares nets $26 mil. to fund a two-year capacity expansion project for the firm's r/LS red blood cell filtration system. The expansion is anticipated to result in a greater-than-ten-fold increase in production capability in order to meet demand for leukoreduced blood products. The project will commence in the second quarter and further the American Red Cross goal of 100% leukoreduction by the end of 2000
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.